Evaluation of Corrected QT Intervals of 74 COVID19 Patients Treated with Hydroxychloroquine in Combination with or without Azithromycin and/or Favipiravir

UYAROĞLU, OĞUZ; ŞENER, YUSUF; ÖZDEDE, MURAT; ÇALIK BAŞARAN, NURSEL; ÖZIŞIK, LALE; ŞAHİN, TAHA; CANPOLAT, UĞUR; İNKAYA, AHMET; YORGUN, HİKMET; SAİN GÜVEN, GÜLAY; AYTEMİR, KUDRET

doi:10.5152/eurjther.2021.21022

Evaluation of Corrected QT Intervals of 74 COVID19 Patients Treated with Hydroxychloroquine in Combination with or without Azithromycin and/or Favipiravir

Atıf İçin Kopyala

UYAROĞLU O. A., ŞENER Y. Z., ÖZDEDE M., ÇALIK BAŞARAN N., ÖZIŞIK L., ŞAHİN T. K., ...Daha Fazla

European Journal of Therapeutics, cilt.27, sa.4, ss.311-317, 2021 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 27 Sayı: 4
Basım Tarihi: 2021
Doi Numarası: 10.5152/eurjther.2021.21022
Dergi Adı: European Journal of Therapeutics
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.311-317
Anahtar Kelimeler: COVID-19, corrected QT, hydroxychloroquine, azithromycin, favipiravir, RISK
Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: We aimed to evaluate the degree of QTc prolongation and associated factors in patients with COVID-19 in association with their usage of hydroxychloroquine (HCQ) with or without the combination of azithromycin (AZ) and/or favipiravir (FAV).